Population aging is associated with an increasing prevalence of chronic diseases(including chronic heart failure) and comorbidities(the presence of one or more diseases in addition to an index disease, potentially contributing to disability) which, in turn, expands the need for healthcare services. Therefore, the already elevated costs in the National Health Services are expected to rise further over the next decades, along with increasing aging of the population. This epidemiologic trend is responsible for the increasing occurrence of polytherapy(multiple medications prescribed to an individual patient) and polypharmacy(multiple medications not directly prescribed by a physician). Owing to often unpredictable interactions, polytherapy and polypharmacy are associated with higher risk of adverse drug reactions with increased mortality and hospitalizations that contribute to increase direct and indirect National Health Services costs. Physicians, patients and caregivers should be instructed in strategies aimed at reducing adverse drug reactions while maintaining optimal management of conditions that, such as chronic heart failure, are at high risk of death, functional impairment and deteriorated quality of life. Strategies consist of a variety of interventions, such as reducing inappropriate medication prescriptions and number of medications and doses taken, avoiding drugs with greater potential of interactions, and increasing patient adherence.

Politerapia e polifarmacia nell'anziano con scompenso cardiaco cronico / N. Ferrara, P. Terrosu, G. Zuccalà, A. Corsini. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1827-6806. - 14:3 suppl. 1(2013), pp. 46S-51S. [10.1714/1261.13940]

Politerapia e polifarmacia nell'anziano con scompenso cardiaco cronico

N. Ferrara;A. Corsini
2013

Abstract

Population aging is associated with an increasing prevalence of chronic diseases(including chronic heart failure) and comorbidities(the presence of one or more diseases in addition to an index disease, potentially contributing to disability) which, in turn, expands the need for healthcare services. Therefore, the already elevated costs in the National Health Services are expected to rise further over the next decades, along with increasing aging of the population. This epidemiologic trend is responsible for the increasing occurrence of polytherapy(multiple medications prescribed to an individual patient) and polypharmacy(multiple medications not directly prescribed by a physician). Owing to often unpredictable interactions, polytherapy and polypharmacy are associated with higher risk of adverse drug reactions with increased mortality and hospitalizations that contribute to increase direct and indirect National Health Services costs. Physicians, patients and caregivers should be instructed in strategies aimed at reducing adverse drug reactions while maintaining optimal management of conditions that, such as chronic heart failure, are at high risk of death, functional impairment and deteriorated quality of life. Strategies consist of a variety of interventions, such as reducing inappropriate medication prescriptions and number of medications and doses taken, avoiding drugs with greater potential of interactions, and increasing patient adherence.
No
English
Chronic heart failure; Drug interactions; Drug polytherapy; Patient adherence; Polypharmacy
Settore BIO/14 - Farmacologia
Articolo
Esperti anonimi
Pubblicazione scientifica
2013
Il Pensiero Scientifico Editore
14
3 suppl. 1
46S
51S
6
Pubblicato
Periodico con rilevanza internazionale
scopus
pubmed
medra
Aderisco
info:eu-repo/semantics/article
Politerapia e polifarmacia nell'anziano con scompenso cardiaco cronico / N. Ferrara, P. Terrosu, G. Zuccalà, A. Corsini. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1827-6806. - 14:3 suppl. 1(2013), pp. 46S-51S. [10.1714/1261.13940]
reserved
Prodotti della ricerca::01 - Articolo su periodico
4
262
Article (author)
no
N. Ferrara, P. Terrosu, G. Zuccalà, A. Corsini
File in questo prodotto:
File Dimensione Formato  
10-Ferrara (46-51).pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 259.09 kB
Formato Adobe PDF
259.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/588541
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
  • OpenAlex ND
social impact